# A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function

> **NCT00976326** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 12 (actual)

## Conditions studied

- Diabetes
- Healthy

## Interventions

- **DRUG:** insulin degludec

## Key facts

- **NCT ID:** NCT00976326
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00976326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00976326, "A Trial Investigating the Pharmacokinetic (Mode of Action in the Body) and Safety Profiles of NN1250 (Insulin Degludec) in Subjects With Various Degrees of Impaired Liver Function and in Subjects With Normal Liver Function". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00976326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*